BioSpace News Archive

Cardinal Health (NYSE: CAH) announced today it has been awarded a $750,000 contract by the U.S. Food and Drug Administration (FDA) to implement an 18-month real world evidence (RWE) study as part of the agency’s efforts to advance the applicability of RWE in regulatory decision-making.

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET ( 1:30 p.m. PT ).

IACTA Pharmaceuticals, Inc. today announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800

Synthekine Inc. today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).

X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries announces their successful up-listing to OTCQB trading status, effective as of the open of trading on October 28, 2021.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced the release of version 9.8.2 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling program, GastroPlus®.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors.

HanAll Biopharma (KRX: 009420.KS) announced today that the company had achieved sales of 25.5 billion won, an operating profit of 2.2 billion won, and a net profit of 2.1 billion won in the third quarter of 2021.

The Muscular Dystrophy Association announced the awarding of 18 new MDA grants totaling over $1.6 million toward neuromuscular disease research.